AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
We assign a fundamental rating of 5 out of 10 to AMED. AMED was compared to 106 industry peers in the Health Care Providers & Services industry. AMED has only an average score on both its financial health and profitability. AMED has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
AMED had positive earnings in the past year.
AMED had a positive operating cash flow in the past year.
AMED had positive earnings in 4 of the past 5 years.
AMED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
AMED has a Return On Assets (2.02%) which is in line with its industry peers.
AMED has a Return On Equity of 3.81%. This is comparable to the rest of the industry: AMED outperforms 57.55% of its industry peers.
AMED has a Return On Invested Capital of 10.19%. This is amongst the best in the industry. AMED outperforms 83.02% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMED is in line with the industry average of 8.79%.
The last Return On Invested Capital (10.19%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 3.81% | ||
| ROIC | 10.19% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
AMED has a better Profit Margin (1.84%) than 60.38% of its industry peers.
In the last couple of years the Profit Margin of AMED has declined.
AMED has a better Operating Margin (8.92%) than 80.19% of its industry peers.
In the last couple of years the Operating Margin of AMED has remained more or less at the same level.
The Gross Margin of AMED (43.34%) is better than 71.70% of its industry peers.
AMED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.92% | ||
| PM (TTM) | 1.84% | ||
| GM | 43.34% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMED is still creating some value.
AMED has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AMED has been increased compared to 5 years ago.
Compared to 1 year ago, AMED has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.80 indicates that AMED is not in any danger for bankruptcy at the moment.
AMED has a better Altman-Z score (3.80) than 76.42% of its industry peers.
AMED has a debt to FCF ratio of 1.76. This is a very positive value and a sign of high solvency as it would only need 1.76 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.76, AMED belongs to the top of the industry, outperforming 84.91% of the companies in the same industry.
A Debt/Equity ratio of 0.30 indicates that AMED is not too dependend on debt financing.
AMED has a better Debt to Equity ratio (0.30) than 64.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.76 | ||
| Altman-Z | 3.8 |
ROIC/WACC1.18
WACC8.65%
2.3 Liquidity
A Current Ratio of 1.23 indicates that AMED should not have too much problems paying its short term obligations.
AMED has a worse Current ratio (1.23) than 62.26% of its industry peers.
A Quick Ratio of 1.23 indicates that AMED should not have too much problems paying its short term obligations.
AMED has a Quick ratio of 1.23. This is comparable to the rest of the industry: AMED outperforms 46.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
AMED shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.47%.
AMED shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.46% yearly.
The Revenue has been growing slightly by 5.01% in the past year.
The Revenue has been growing slightly by 3.73% on average over the past years.
EPS 1Y (TTM)0.47%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%2.13%
Revenue 1Y (TTM)5.01%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.78%
3.2 Future
Based on estimates for the next years, AMED will show a small growth in Earnings Per Share. The EPS will grow by 7.37% on average per year.
AMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.07% yearly.
EPS Next Y11.14%
EPS Next 2Y10.35%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue Next Year4.42%
Revenue Next 2Y4.87%
Revenue Next 3Y5.07%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.29, AMED is valued on the expensive side.
AMED's Price/Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 66.04% of the companies in the same industry.
When comparing the Price/Earnings ratio of AMED to the average of the S&P500 Index (28.29), we can say AMED is valued slightly cheaper.
With a Price/Forward Earnings ratio of 19.16, AMED is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 67.92% of the companies listed in the same industry.
AMED is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.08, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.29 | ||
| Fwd PE | 19.16 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than 65.09% of the companies in the same industry.
77.36% of the companies in the same industry are more expensive than AMED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.05 | ||
| EV/EBITDA | 11.42 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMED does not grow enough to justify the current Price/Earnings ratio.
AMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.91
PEG (5Y)N/A
EPS Next 2Y10.35%
EPS Next 3Y7.37%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
91.76
-0.15 (-0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners91.9%
Inst Owner Change0.05%
Ins Owners1.76%
Ins Owner Change5.16%
Market Cap3.01B
Analysts54.12
Price Target98.94 (7.82%)
Short Float %9%
Short Ratio9.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.07%
Min EPS beat(2)-15.99%
Max EPS beat(2)-10.15%
EPS beat(4)1
Avg EPS beat(4)-4.48%
Min EPS beat(4)-15.99%
Max EPS beat(4)9.21%
EPS beat(8)3
Avg EPS beat(8)-0.71%
EPS beat(12)6
Avg EPS beat(12)2.06%
EPS beat(16)8
Avg EPS beat(16)2.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.04%
Min Revenue beat(2)-2.05%
Max Revenue beat(2)-2.02%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.05%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-2.02%
Revenue beat(12)1
Avg Revenue beat(12)-2.87%
Revenue beat(16)1
Avg Revenue beat(16)-2.87%
PT rev (1m)-0.39%
PT rev (3m)-0.39%
EPS NQ rev (1m)-0.94%
EPS NQ rev (3m)-1.53%
EPS NY rev (1m)-3.97%
EPS NY rev (3m)-4.53%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)-0.88%
Revenue NY rev (1m)-0.71%
Revenue NY rev (3m)-0.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.29 | ||
| Fwd PE | 19.16 | ||
| P/S | 1.28 | ||
| P/FCF | 14.05 | ||
| P/OCF | 13.58 | ||
| P/B | 2.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.42 |
EPS(TTM)4.31
EY4.7%
EPS(NY)4.79
Fwd EY5.22%
FCF(TTM)6.53
FCFY7.12%
OCF(TTM)6.76
OCFY7.36%
SpS71.57
BVpS34.58
TBVpS-4.89
PEG (NY)1.91
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 3.81% | ||
| ROCE | 12.9% | ||
| ROIC | 10.19% | ||
| ROICexc | 12.53% | ||
| ROICexgc | 635.86% | ||
| OM | 8.92% | ||
| PM (TTM) | 1.84% | ||
| GM | 43.34% | ||
| FCFM | 9.13% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score7
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.76 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 12.19% | ||
| Cap/Sales | 0.31% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 82.09% | ||
| Profit Quality | 495.69% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | 3.8 |
F-Score7
WACC8.65%
ROIC/WACC1.18
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.47%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%2.13%
EPS Next Y11.14%
EPS Next 2Y10.35%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue 1Y (TTM)5.01%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.78%
Revenue Next Year4.42%
Revenue Next 2Y4.87%
Revenue Next 3Y5.07%
Revenue Next 5YN/A
EBIT growth 1Y21.19%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year17.41%
EBIT Next 3Y9.44%
EBIT Next 5YN/A
FCF growth 1Y72.16%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y61.58%
OCF growth 3Y5.48%
OCF growth 5Y1.88%